Adlai Nortye Ltd. is a global clinical stage biopharmaceutical company that focuses on the discovery and development of innovative cancer therapies. The company was founded in 2004 in mainland China and later rebranded in 2016 to emphasize its shift toward research and development driven oncology. It maintains research and development operations in both the United States and China allowing it to draw on scientific expertise from two major biopharmaceutical hubs. The company's pipeline is built around two primary therapeutic areas. The first area is RAS targeting therapy which includes AN9025 an oral small molecule pan RAS(ON) inhibitor currently in phase I clinical trials and AN4035 a CEACAM5 targeting antibody drug conjugate designed to deliver a pan RAS(ON) inhibitor directly to tumor cells with an IND submission anticipated in the middle of 2026. The second area is next generation cancer immunotherapy which comprises AN8025 a tri specific antibody fusion protein that modulates T cell and antigen presenting cell functions AN4005 an oral small molecule PD L1 inhibitor presently in an expansion phase clinical trial and AN0025 a small molecule EP4 antagonist that is being evaluated in a phase II study known as ARTEMIS for rectal cancer. All of these candidates are undergoing clinical or preclinical evaluation to assess safety efficacy and potential therapeutic benefit.

Adlai Nortye Ltd. does not yet have any commercialized products and therefore does not generate revenue from direct product sales. Its revenue stream is derived from a series of collaboration and licensing agreements that provide upfront payments milestone payments and potential royalties. The agreement with Eisai concerning AN0025 includes an upfront payment of up to US$6.0 million which has already been paid in May and June 2018 and provides for milestone payments that could reach an aggregate amount of approximately US$367 million upon achievement of sales and development milestones. The collaboration with ASK Pharm for AN9025 grants ASK Pharm exclusive rights in mainland China Hong Kong and Macao and entitles Adlai Nortye to receive total consideration of up to RMB1.6 billion equivalent to about US$230 million including an upfront payment and near term milestone payments exceeding US$20 million plus tiered royalties ranging from a high single digit to mid teens percentage of net product sales. The arrangement with Biotime covering AN4005 and other early stage programs provides for an aggregated down payment of up to RMB295.0 million roughly US$46.0 million which has already been received and additional milestone payments in the aggregate amount of RMB835.0 million about US$129.0 million contingent on development and sales targets as well as royalty payments at remuneration rates ranging from mid single digits to mid teens. The worldwide license with WuXi Biologics grants Adlai Nortye a non exclusive right to use certain anti PD L1 related technologies and provides for an upfront payment and eligibility for up to $86.75 million in aggregate development regulatory and commercial milestone payments together with tiered royalties from low to mid single digit percentages on net sales of licensed products. As of the latest reporting date the company has collected the upfront and milestone payments outlined in these agreements and continues to be eligible for further payments as its programs advance.

Adlai Nortye Ltd. operates in the highly competitive oncology sector where it faces competition from large pharmaceutical companies biotechnology firms academic research groups and government entities. These competitors are pursuing therapies that target RAS driven cancers and modulate immune responses. The company's competitive position is strengthened by its dual research and development footprint in the United States and China which provides access to diverse scientific talent patient populations and clinical trial sites. Its intellectual property estate is substantial with granted and pending patents covering its lead candidates AN9025 AN4035 AN8025 AN4005 and AN0025 in jurisdictions such as the United States Europe China Japan South Korea Canada Australia and others. This patent protection helps safeguard its innovations against infringement and supports long term exclusivity. The leadership team brings deep industry experience; founder Yang Lu has a background in entrepreneurship and operations while Dr Archie Tse previously held senior research and development roles at major multinational pharmaceutical firms including MSD and Daiichi Sankyo. Together these factors give Adlai Nortye a differentiated profile in a sector where scientific novelty and execution speed are critical.

The company's current customers are primarily its collaboration partners which include ASK Pharm Biotime WuXi Biologics and Eisai. These partners engage in licensing development manufacturing and commercialization activities for Adlai Nortye's drug candidates in specific geographic territories. Under the Eisai agreement for AN0025 Adlai Nortye holds exclusive rights to develop and commercialize the product worldwide except for Japan Korea Taiwan Thailand India Philippines Indonesia Singapore Malaysia Vietnam Myanmar Laos and Cambodia. The ASK Pharm collaboration grants ASK Pharm exclusive rights in mainland China Hong Kong and Macao for AN9025 while Adlai Nortye retains worldwide rights outside that region. The Biotime arrangement covers AN4005 and other early stage programs in China and provides for global development of three additional early stage initiatives. The WuXi Biologics license provides a non exclusive right to use certain anti PD L1 technologies for the creation of multifunctional antibodies worldwide. In addition to these partnership arrangements Adlai Nortye works with contract research organizations to design and execute its clinical studies and with contract manufacturing organizations to produce drug substance for preclinical and clinical supply. Upon successful regulatory approval the company anticipates that its eventual customers will be hospitals clinics physicians and patients who require oncology therapies especially those suffering from RAS driven malignancies or immune resistant tumors.